Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
The need-to-know this morning Abeona Therapeutics said the FDA approved its cell-based gene therapy for patients with recessive dystrophic epidermolysis bulosa, a rare skin condition that causes blistering wounds
Weeks 2-4: Appetite Effects Build, Early Weight Separation What the trials documented: Across the Phase 2 dose-finding trial, weight in the cagrilintide arms began separating from placebo during the initial weeks of titration, with the gap widening at every dose level as the study progressed (Lau et al., 2021)
Insulin gene expression is upregulated in pancreatic -cells after GLP-1R activation, which increases insulin mRNA expression through activation of transcription factors such as pancreatic and duodenal homeobox-1 and cAMP-response element binding protein (Habener and Stoffers, 1998)
Clinical trials show average weight loss of 15-20% of body weight over 68 weeks with semaglutide (Wegovy) and 15-22% with tirzepatide (Zepbound)
What this is not This is not a reason to rush into enrolling before a deadline
Though rare, interactions can occur, such as with hormonal birth control
US$ 29.03
US$ 23.12
US$ 25.94
US$ 25.36
US$ 23.69
